An open-label, randomized, and multicenter phase 2 study is being planned to further evaluate the regimen of ropeg and anti-PD-1 treatment as adjuvant treatment for post-surgical recurrence of viral-related HCC. Here, PDCD1 is linked to hepatocellular carcinoma.